Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018

Details for Mechanism ID: 18234
Country/Region: Malawi
Year: 2016
Main Partner: Right to Care
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $20,724,217 Additional Pipeline Funding: $2,022,543

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $1,249,773
Care: TB/HIV (HVTB) $2,492,546
Care: Pediatric Care and Support (PDCS) $980,850
Laboratory Infrastructure (HLAB) $207,712
Strategic Information (HVSI) $204,212
Health Systems Strengthening (OHSS) $103,857
Testing: HIV Testing and Counseling (HVCT) $623,136
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $830,849
Treatment: Adult Treatment (HTXS) $10,650,176
Treatment: Pediatric Treatment (PDTX) $3,381,106
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTS_TST Age/sex: <1 2017 60,069
HTS_TST Age/sex: 1-9 2017 479,418
HTS_TST Age/sex: 10-14 Female 2017 104,418
HTS_TST Age/sex: 10-14 Male 2017 101,261
HTS_TST Age/sex: 15-19 Female 2017 87,331
HTS_TST Age/sex: 15-19 Male 2017 83,592
HTS_TST Age/sex: 20-24 Female 2017 73,363
HTS_TST Age/sex: 20-24 Male 2017 69,510
HTS_TST Age/sex: 25-49 Female 2017 211,855
HTS_TST Age/sex: 25-49 Male 2017 198,346
HTS_TST Age/sex: 50+ Female 2017 73,225
HTS_TST Age/sex: 50+ Male 2017 63,610
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 372,684
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 372,497
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 445,775
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 415,042
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 1,605,998
HTS_TST Service Delivery Point (Facility): Inpatient 2017 104,391
HTS_TST Service Delivery Point (Facility): Other PITC 2017 456,104
HTS_TST Service Delivery Point (Facility): Pediatric 2017 284,267
HTS_TST Service Delivery Point (Facility): PMTCT 2017 456,104
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 14,450
HTS_TST Service Delivery Point (Facility): VCT 2017 290,682
HTS_TST Sum of Age/Sex disaggregates 2017 1,066,511
HTS_TST Sum of Aggregated Age/Sex <15 2017 745,181
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 860,817
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 1,605,998
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Female 2017 1,683
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 1,637
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Female 2017 10,397
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 9,945
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Female 2017 8,735
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 8,269
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Female 2017 25,231
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 23,616
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Female 2017 8,720
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 7,575
HTS_TST_POS Test Result by Age: Positive: <1 2017 968
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 7,742
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 6,026
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 6,024
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 53,067
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 49,423
PMTCT_ART Already on ART at beginning of current pregnancy 2017 15,548
PMTCT_ART New on ART 2017 14,333
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 256,200
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 8,006
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 13,630
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 396
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 225
PMTCT_EID Sum of Infant Age disaggregates 2017 21,636
PMTCT_STAT By Age (DREAMS SNUs ONLY): <15 2017 723
PMTCT_STAT By Age (DREAMS SNUs ONLY): 15-19 2017 54,112
PMTCT_STAT By Age (DREAMS SNUs ONLY): 20-24 2017 85,854
PMTCT_STAT By Age (DREAMS SNUs ONLY): 25-49 2017 85,848
PMTCT_STAT By Age (DREAMS SNUs ONLY): 50+ 2017 29,663
PMTCT_STAT By: Known positives at entry 2017 17,148
PMTCT_STAT By: Number of new positives identified 2017 14,610
PMTCT_STAT Number of new ANC and L&D clients 2017 273,977
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 256,200
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: <15 2017 3,626
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 15-19 2017 19
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 20-24 2017 5,742
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 25-49 2017 5,768
PMTCT_STAT Required only for DREAMS Countries - By Number of known positives: 50+ 2017 1,993
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: <15 2017 8
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 15-19 2017 3,087
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 20-24 2017 4,890
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 25-49 2017 4,936
PMTCT_STAT Required only for DREAMS Countries - By Number of new positives: 50+ 2017 1,689
PMTCT_STAT Sum of Positives Status disaggregates 2017 31,758
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15 2017 773
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: <15-19 2017 57,873
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 20-24 2017 91,813
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 25-49 2017 91,791
PMTCT_STAT_den Required only for DREAMS Countries - Denominator: 50+ 2017 31,727
TB_ART Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 118
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1,576
TB_ART Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 59
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 857
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 2,871
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 2,610
TB_SCREENDX [Sub-Disagg of Screen Result] Specimen Sent: Specimen sent for bacteriologic diagnosis of active TB 2017 238,999
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: other (not Xpert) 2017 21,579
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Smear only 2017 195,512
TB_SCREENDX [Sub-Disagg of Specimen Sent] Diagnostic Test: Xpert MTB/RIF assay 2017 21,908
TB_SCREENDX Screen Result: Screened Positive for TB 2017 3,265
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 197,190
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 108,916
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 13,427
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 7,413
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 326,946
TB_STAT Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 338
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 4,775
TB_STAT Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 184
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2,621
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 7,918
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 8,528
TX_CURR Age/Sex: <1 2017 5,056
TX_CURR Age/Sex: <1-9 2017 22,154
TX_CURR Age/Sex: 10-14 Female 2017 5,087
TX_CURR Age/Sex: 10-14 Male 2017 4,641
TX_CURR Age/Sex: 15-19 Female 2017 11,347
TX_CURR Age/Sex: 15-19 Male 2017 2,428
TX_CURR Age/Sex: 20-24 Female 2017 35,680
TX_CURR Age/Sex: 20-24 Male 2017 4,033
TX_CURR Age/Sex: 25-49 Female 2017 143,581
TX_CURR Age/Sex: 25-49 Male 2017 83,741
TX_CURR Age/Sex: 50+ Female 2017 11,468
TX_CURR Age/Sex: 50+ Male 2017 14,939
TX_CURR Aggregated Age/Sex: <15 Female 2017 19,019
TX_CURR Aggregated Age/Sex: <15 Male 2017 17,929
TX_CURR Aggregated Age/Sex: 15+ Female 2017 195,008
TX_CURR Aggregated Age/Sex: 15+ Male 2017 112,199
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 344,155
TX_CURR Sum of age/sex disaggregates 2017 13,775
TX_CURR Sum of Aggregated Age/Sex <15 2017 36,948
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 307,207
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 344,155
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 4,149
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 3,912
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 53,619
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 29,761
TX_NEW By Age/Sex: <1 2017 1,102
TX_NEW By Age/Sex: 1-9 2017 4,835
TX_NEW By Age/Sex: 10-14 Female 2017 1,119
TX_NEW By Age/Sex: 10-14 Male 2017 1,011
TX_NEW By Age/Sex: 15-19 Female 2017 3,015
TX_NEW By Age/Sex: 15-19 Male 2017 640
TX_NEW By Age/Sex: 20-24 Female 2017 9,453
TX_NEW By Age/Sex: 20-24 Male 2017 1,077
TX_NEW By Age/Sex: 25-49 Female 2017 38,088
TX_NEW By Age/Sex: 25-49 Male 2017 24,083
TX_NEW By Age/Sex: 50+ Female 2017 3,050
TX_NEW By Age/Sex: 50+ Male 2017 3,968
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 91,441
TX_NEW Sum of Age/Sex disaggregates 2017 85,504
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 91,441
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 120,454
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 108,398
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 5,027
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 4,738
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 63,423
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 35,210
TX_PVLS Numerator: Indication: Routine 2017 97,569
TX_PVLS Numerator: Indication: Targeted 2017 41
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 5,581
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 5,258
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 70,491
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 39,124
TX_PVLS_den Denominator: Indication: Routine 2017 108,398
TX_PVLS_den Denominator: Indication: Targeted 2017 47
TX_RET Age/Sex: <1 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 638
TX_RET Age/Sex: 1-9 (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,820
TX_RET Age/Sex: 10-14 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 648
TX_RET Age/Sex: 10-14 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 596
TX_RET Age/Sex: 15-19 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,978
TX_RET Age/Sex: 15-19 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 429
TX_RET Age/Sex: 20-24 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 6,209
TX_RET Age/Sex: 20-24 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 692
TX_RET Age/Sex: 25-49 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 24,992
TX_RET Age/Sex: 25-49 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 15,797
TX_RET Age/Sex: 50+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,996
TX_RET Age/Sex: 50+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,598
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,356
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,220
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 35,777
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 19,040
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 59,393
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 65,406
TX_RET_den Age/Sex: >1 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 704
TX_RET_den Age/Sex: 1-9 (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 3,107
TX_RET_den Age/Sex: 10-14 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 713
TX_RET_den Age/Sex: 10-14 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 651
TX_RET_den Age/Sex: 15-19 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,180
TX_RET_den Age/Sex: 15-19 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 472
TX_RET_den Age/Sex: 20-24 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6,835
TX_RET_den Age/Sex: 20-24 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 768
TX_RET_den Age/Sex: 25-49 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 27,507
TX_RET_den Age/Sex: 25-49 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 17,402
TX_RET_den Age/Sex: 50+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,201
TX_RET_den Age/Sex: 50+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,866
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,596
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 2,451
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 39,392
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 20,967
Cross Cutting Budget Categories and Known Amounts Total: $1,440,000
Food and Nutrition: Policy, Tools, and Service Delivery $100,000
Renovation $100,000
Human Resources for Health $500,000
Gender: Gender Based Violence (GBV) $500,000
Post GBV Care
Collection and Use of Gender-related Strategic Information
Capacity building
Motor Vehicles: Purchased $240,000